Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 31-40 results of 45
Head and Neck Cancer

NRG / HN011

Official Title: A Randomized Phase II Study of Nivolumab Versus Nivolumab and Relatlimab as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
Study Purpose: To determine if adding Relatlimab to Nivolumab maintenance therapy improves progression-free survival following first-line treatment of recurrent and/or metastatic nasopharyngeal carcinoma.
Status: Recruiting
Lung Cancer

NRG / LU007

Official Title: Testing The Addition Of Radiation Therapy To The Usual Immune Therapy Treatment (Atezolizumab) For Patients With Extensive Stage Small Cell Lung Cancer
Study Purpose: To determine if can we extend the time without your extensive small cell lung cancer growing or spreading by adding radiation therapy to the usual treatment for this type of cancer.
Status: Recruiting
Lung Cancer

NRG / LU008

Official Title: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer 
Study Purpose: To compare overall survival in patients with Stage II-IIIC inoperable Non-small cell lung cancer comparing conventional radiation with chemotherapy  to stereotactic body radiation and conventional  radiation along with chemotherapy
Status: Recruiting
Gynecologic Cancer

NRG GY025

Official Title: A Randomized Phase II Trial of Nivolumab and Ipilimumab compared to Nivolumab Monotherapy in patients with deficient mismatch repair system recurrent endometrial carcinoma.
Study Purpose: To find out if combining two immunotherapy drugs, nivolumab and ipilimumab, is better or worse than the usual approach with a single immunotherapy agent.
Status: Recruiting
Skin Cancer

NRG HN014

Official Title: Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma 
Study Purpose: To test if giving immunotherapy before and after (in some cases) surgery extend the length of time without your cancer returning compared to the usual approach 
Status: Recruiting
Head and Neck Cancer

NRG HN015

Official Title: A PHASE II RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY OR CHEMO-IMMUNOTHERAPY IN PATIENTS WITH RECURRENT/PERSISTENT PD-L1 ENRICHED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK UNDERGOING SALVAGE SURGERY (NEOPOLIS)
Study Purpose: To assess and compare the long term outcome and side effects of patients treated with:chemotherapy (carboplatin + paclitaxel) prior to salvage surgery (SS) orchemo-immunotherapy (carboplatin +paclitaxel + cemiplimab) prior to salvage surgery (SS) orpatients undergoing standard of care salvage surgery (SS) alone.
Status: Recruiting
Gynecologic Cancer

NRG-GY032

Official Title: A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER)
Study Purpose: To determine if there are types of early-stage endometrial cancer that require less post-surgical treatment than the usual approach.
Status: Recruiting
Gynecologic Cancer

NRG-GY036

Official Title: A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY
Study Purpose: To study if the use of Olaparib for one year keeps your ovarian cancer from growing or returning as well as the usual approach of two years.
Status: Recruiting
Gynecologic Cancer

NRG-GY037

Official Title: A Phase III study of induction pembrolizumab and chemotherapy followed by pembrolizumab before chemoradiation and pembrolizumab maintenance compared to standard chemoradiation with pembrolizumab followed by pembrolizumab maintenance in high-risk cervical cancer
Study Purpose: To find out if adding an immunotherapy drug plus chemotherapy before starting the usual combination of chemotherapy and radiation will increase overall survival or improve recurrence-free survival from cervical cancer.
Status: Recruiting
Breast Cancer

Personalis / 01-PS-001

Official Title: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
Study Purpose: Evaluate the correlation of Minimal Residual Disease detection by NeXT Personal CTA (a molecular test) to pathological Complete Response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC)
Status: Recruiting